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Sporadic cases of colorectal cancer are primarily initiated by gene mutations in members of the canonical Wnt pathway, ultimately
resulting in b-catenin stabilisation. Nevertheless, cells displaying nuclear b-catenin accumulation are nonrandomly distributed
throughout the tumour mass and preferentially localise along the invasive front where parenchymal cells are in direct contact with the
stromal microenvironment. Here, we discuss the putative role played by stromal cell types in regulating b-catenin intracellular
accumulation in a paracrine fashion. As such, the tumour microenvironment is likely to maintain the cancer stem cell phenotype in a
subset of cells, thus mediating invasion and metastasis.
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In the intestinal tissue architecture, epithelial cells lining the
luminal surface are tightly regulated to ensure homeostasis.
Epithelial cell renewal is fuelled by an adult stem cell compartment
localised at the bottom of the crypt (Potten and Loeffler, 1990;
Barker et al, 2007). As cells migrate upwards, after a transient
proliferative phase, the epithelium differentiates into specialised
cell types including absorptive enterocytes, mucus secreting goblet
cells, and enteroendocrine cells. This migratory process with
concomitant differentiation is finalised when cells reach the top of
the crypt where they are exfoliated into the lumen upon apoptosis.
In the upper gastrointestinal tract, Paneth cells represent an
exception as they move downwards while differentiating. Overall,
cell renewal, proliferation, and differentiation are coupled to
positional localisation along the crypt-to-villus axis. In fact, this
positional regulation of proliferation and differentiation can be
correlated to gradients in the degree of activity of several signalling
pathways known to govern stemness and differentiation, including
Wnt/b-catenin, bone morphogenic protein (BMP), Notch, and
transforming growth factor-b (TGFb; Crosnier et al, 2006). The
mesenchyme plays a complex role in the positional gradient of
signalling ligand availability. Intestinal subepithelial myofibro-
blasts are specialised stromal cells that form a continuous sheet
directly localised underneath the mucosa. These myofibroblasts
contribute to epithelial cell function by providing mechanical
support and secreting key signalling ligands. Thus, the intimate
interaction between the parenchyme and mesenchyme ensures
proper tissue function, balancing cell renewal, and differentiation.
Activation of canonical Wnt signalling characterises the base of the
intestinal crypt as shown by the nuclear b-catenin localisation
crypt cells (Figure 1). Note that Paneth cells in the small intestine
also show nuclear b-catenin accumulation as previously reported
(Van Es et al, 2005). Moving upwards along the crypt-to-villus
axis, terminal differentiation coincides with the more restricted
membrane-bound b-catenin localisation and its absence in the
nucleus and cytosol (Figure 1). Recently, it has been reported that
the BMP antagonists, gremlin 1, gremlin 2, and chrodin-like 1, are
selectively expressed by crypt-based myofibroblasts and smooth
muscle cells (Kosinski et al, 2007). Moreover, Gremlin 1 was shown
to activate Wnt/b-catenin signalling in normal rat intestinal
epithelial cells, thus indicating that stromal-derived factors
regulate Wnt/b-catenin-signalling activity in the intestinal stem
cell niche.
Upon constitutive activation of the Wnt signalling route,
intestinal homeostasis is disturbed, paving the way for pathogen-
esis. Indeed, the vast majority of sporadic colorectal cancer cases is
caused by constitutive Wnt activation due to mutations in either
the APC tumour suppressor or the b-catenin (CTNNB1) oncogene
(Fodde et al, 2001). Loss of APC function leads to destabilisation of
the ‘destruction complex’, a multiprotein complex encompassing
three scaffold proteins, APC, Axin1, and Axin2 (conductin), and
two kinases, glycogen synthase kinase-3b (GSK3b) and casein
kinase 1 (CK1). The complex binds and phosphorylates b-catenin
at serine and threonine residues, thus targeting it for ubiquitina-
tion and proteolytic degradation. In contrast, oncogenic mutations
in b-catenin render it resistant to Ser/Thr phosphorylation and
proteolytic degradation. Upon its cytoplasmic stabilisation and
subsequent nuclear translocation, b-catenin binds to members of
the TCF/LEF family of transcription factors, thus modulating
expression of a broad range of target genes (http://www.stanford.
edu/~rnusse/pathways/targets.html). Although the presence of
these initiating mutations predicts nuclear b-catenin accumulation
throughout the tumour mass, heterogeneous intracellular distribu-
tions are observed within primary colorectal tumours and their
metastases. In particular, tumour cells located at the invasive front
and those migrating into the adjacent stromal tissue are earmarked
by nuclear b-catenin accumulation (Brabletz et al, 1998, 2001;
Figure 1). Hence, different levels of Wnt/b-catenin-signalling
activity are likely to reflect tumour heterogeneity and to underlie
Received 7 January 2008; accepted 8 April 2008; published online 27 May
2008
*Correspondence: Dr R Fodde; E-mail: r.fodde@erasmusmc.nl
British Journal of Cancer (2008) 98, 1886–1893
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.commalignant behaviour (Gaspar and Fodde 2004; Brabletz et al,
2005a).
Several intrinsic (cell autonomous and/or autocrine) and
extrinsic (paracrine, derived from the tumour microenvironment)
factors may explain the observed heterogeneity of Wnt/b-catenin-
signalling activity within the tumour mass (Fodde and Brabletz,
2007). Here, we discuss stromal factors likely to play a role in the
heterogeneous b-catenin intracellular localisation and signalling
activity in tumour cells. As such, the tumour microenvironment
may drive tumour growth and even selectively support a subset
of tumour cells, the cancer stem cells (CSCs), thus actively
contributing to malignancy.
STROMAL CELLS AFFECTING TUMOUR GROWTH,
NUCLEAR b-CATENIN ACCUMULATION, AND
CANCER STEMNESS
As stated above, stromal regulation significantly contributes to
the preservation of normal tissue architecture. Myofibroblasts,
for example, are not only tightly associated with the intestinal
epithelium thus ensuring homeostasis through reciprocal
interactions, but are also essential for wound healing upon tissue
injury, when they are transiently enriched and activated (Gabbiani,
2003). Expression of a-smooth muscle actin (a-SMA) characterises
these myofibroblasts and underlies contractile force tension that
facilitates healing. Myofibroblasts produce a variety of growth
factors, prostaglandins, cytokines, chemokines, and extracellular
matrix components that facilitate tissue repair and survival.
Myofibroblasts arise through a multitude of processes, including
transdifferentiation of resident fibroblasts, epithelial-to-mesen-
chymal transition (EMT) of parenchymal cells, recruitment, and
differentiation of pericytes (progenitor cells localised at vascular
sinuses), and from bone marrow-derived circulating immature
fibrocytes (Desmouliere et al, 2004). Upon completion of the
wound healing process, myofibroblasts revert back to their
dormant state. In fact, tumorigenesis has been described as a
condition comparable to an open wound of chronic nature
(Dvorak, 1986). Accordingly, fibroblasts are one of the most
abundant cell types in the stromal microenvironment associated
with solid tumours (Adegboyega et al, 2002; De Wever and Mareel,
2003; Kalluri and Zeisberg, 2006). In response to the malignant
lesion within the epithelial compartment, stromal fibroblasts
become morphologically ‘activated’. Similar to the wound-healing
process, an activated response of the tumour stroma may initially
be triggered in an attempt to restore tissue homeostasis. However,
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Figure 1 b-Catenin immunohistochemical staining of formalin-fixed, paraffin-embedded normal human colonic epithelia (panels A and B), and of a
primary colorectal tumour (panels C and D) and a liver metastasis (panels E and F). The right panels contain magnifications ( 40) of specific areas from the
left panels ( 20). The arrowheads in panels A and B indicate an epithelial cell localised at the base of the crypt with nuclear b-catenin accumulation. Both
the primary colorectal tumour and liver metastasis (panels C–F) show nuclear b-catenin accumulation in cells invading the surrounding stroma, whereas
other tumour cells display only membranous localisation.
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become a ‘partner in crime’ in malignancy. A subset of tumour
stromal fibroblasts, also referred to as cancer-associated fibro-
blasts (CAFs), peritumoral fibroblasts, reactive stromal fibroblasts,
tumour-associated fibroblasts, or myofibroblasts, acquire distinct
phenotypic characteristics. These cells share many of the proper-
ties of normal myofibroblasts such as a-SMA expression and
increased production of growth factors, and of a variety of matrix
remodelling proteases, which facilitate migration and invasion of
the tumour cells (De Wever and Mareel, 2003; Desmouliere et al,
2004; Mukaratirwa et al, 2005). In view of their specific growth
promoting effects, CAFs are primary candidates for locally
modulating Wnt/b-catenin signalling, resulting in heterogeneous
patterns of b-catenin intracellular localisation within colorectal
tumours (Brabletz et al, 2001). Convergence of CAFs in specific
regions of the tumour may provide a local increase in ligand
availability that directly, in the case of Wnt ligands, or indirectly,
in the case of growth factors, prostaglandins, and chemokines, may
cross talk with and increase Wnt/b-catenin signalling.
Cross talk of a variety of factors has been reported to modulate
nuclear b-catenin accumulation. For instance, hepatocyte growth
factor or scatter factor (HGF, SF) induces b-catenin stabilisation in
colorectal cancer cells via c-MET-dependent inhibition of GSKb
activity and its Tyr phosphorylation (Rasola et al, 2007). Tyr
phosphorylation of b-catenin leads to its stabilisation and nuclear
signalling activity by decreasing its binding affinity to E-cadherin
and the APC/GSKb/Axin destruction complex (Coluccia et al,
2007). Platelet-derived growth factor (PDGF) stimulation of HT-29
colorectal cancer cells increases b-catenin activation via p68-
dependent inhibition of Ser/Thr phosphorylation by GSK3b (Yang
et al, 2006).
In addition to the secretion of growth factors capable of
modulating b-catenin stabilisation during tumour growth and
local invasion, CAFs may also play a significant role in the
metastatic process. As stated above, these cells can originate from
circulating precursor cells recruited from the bone marrow, often
referred to as fibrocytes. Therefore, these mesenchymal cells may
not only exert local effects within the tumour, but could also
represent systemic effectors relevant for the metastatic process by
functioning as carrier cells during extravasation of tumour cells
and/or ‘landscaping’ secondary organ sites where circulating
tumour cells can home to and form secondary outgrowths. This
may be of particular importance in view of the CSC hypothesis,
which predicts that only a subset of tumour cells, displaying stem
cell characteristics, will be successful in invading surrounding
tissues and forming metastases in secondary organs. We have
previously postulated that cancer stemness may be conferred by
specific levels of b-catenin activation in colorectal cancer (Brabletz
et al, 2005a; Fodde and Brabletz, 2007). Stromal cells may play a
significant role by providing a supportive microenvironment that
maintains CSCs at the primary tumour site and also underlies their
invasive behaviour and spreading to distant sites. Karnoub et al
(2007) have recently shown that bone marrow-derived mesen-
chymal stem cells can indeed increase metastatic potency of breast
tumour cells. In addition, Kaplan et al (2005) have reported that
haematopoietic progenitor cells expressing vascular endothelial
growth factor receptor-1 are recruited and home to premetastatic
niches prior to the arrival of tumour cells in mice injected with
Lewis lung carcinoma or B16 melanoma cells. This response
directs the metastatic pattern and is triggered by tumour-specific
secreted factors. These data indicate that stromal (precursor) cells
are active coconspirators in malignancy by increasing metastatic
potential of tumour cells and providing a ‘congenial soil’ for
secondary growth.
As stromal cells may significantly modulate both tumour
growth and nuclear b-catenin accumulation and thus represent a
cancer stemness determinant, specific stromal cell characteristics
may be selected during tumorigenesis to provide a supportive
microenvironment for pathogenic events. For instance, selective
pressure from the tumour promotes genetic loss of p53 in stromal
fibroblasts giving rise to highly proliferative stromal compart-
ments in a mouse model for prostate cancer (Hill et al, 2005).
Transforming growth factor-bis also highly expressed in most
solid tumours and is capable of transforming fibroblasts towards
an activated phenotype (De Wever and Mareel, 2003; Mishra et al,
2005; Orimo and Weinberg, 2006). Accordingly, stromal expres-
sion of the TGF-b type II receptor (TGFRII) reflects its activation
by TGFb stimulation and directly correlates with prognosis and
survival in human colorectal cancer (Bacman et al, 2007). Stromal
abrogation of TGFRII leads to prostate and stomach tumours in a
murine model (Bhowmick et al, 2004). Moreover, expression of
PDGFR (platelet-derived growth factor receptor) in stromal cells
directly correlates with advanced stage disease in human colorectal
cancer (Kitadai et al, 2006a). Both a DNA vaccine against PDGFRb
(Kaplan et al, 2006) as well as PDGFR inhibition by imatinib
alone or in combination with irinotecan (Kitadai et al, 2006b),
suppressed growth and dissemination of human colorectal cancer
cells injected into mice, suggesting that increased PDGF signalling
to stromal cells is a determinant for malignancy. Therefore,
reciprocal interactions between tumour cells and the micro-
environment facilitate tumour growth, invasion, and metastasis,
by selecting not only for tumour cells capable of invasion and
metastasis, but also for a stromal cell compartment that optimally
supports the malignant phenotype.
In line with the above, EMT drives tumour cells towards a more
mesenchymal phenotype and is implicated in invasive and
malignant behaviour. It has been shown that colorectal cancer
cells with nuclear b-catenin accumulation clustered along the
invasive front undergo EMT as they detach from the tumour
mass and invade the surrounding stroma (Brabletz et al, 2005b).
Moreover, hepatocytes that have undergone TGFb-induced EMT
and have acquired a fibroblastoid phenotype, show nuclear
b-catenin accumulation, proliferation, and migration upon PDGF
treatment (Fischer et al, 2007). S100A4, a mesenchymal gene
expressed during EMT and associated with poor prognosis in
colorectal cancer, is in itself a target gene of Wnt/b-catenin
signalling (Stein et al, 2006). Therefore, EMT may determine a
‘double jeopardy’ effect: CSCs earmarked by nuclear b-catenin
accumulation can transdifferentiate, thus generating a permissive
niche capable of eliciting nuclear b-catenin translocation in other
parenchymal cells located in direct contact with the stromal
tumour microenvironment.
IMMUNE CELLS AND ADIPOCYTES MODULATING
TUMOUR GROWTH
Besides stromal fibroblasts, the tumour microenvironment
consists of a variety of cell types capable of modulating tumour
growth and possibly cancer stemness. Tumour-infiltrating innate
and adoptive immune cells may confer both tumour-growth-
promoting and -inhibiting effects (de Visser et al, 2006).
Intuitively, increased infiltration of T cells should correlate with
improved tumour clearance and prognosis, as recently reported in
colorectal cancer cohorts (Pages et al, 2005; Clarke et al, 2006;
Galon et al, 2006). However, a subtype of T cells, termed regulatory
T cells (Tregs), are likely to exert tumour-growth-promoting
effects due to their immune suppressive function to mediate self-
tolerance, prevent autoimmunity, and enable the presence of a
commensal bacterial flora in the intestine (Powrie, 2004).
Regulatory T cells have been reported to be increased in peripheral
blood and infiltrating lymphocytes among colorectal cancer
patients (Ling et al, 2007). The increased presence of these Tregs
sets the stage for immune evasion by tumour cells.
Several other tumour-infiltrating immune cells have been
reported to support tumour growth, including tumour-associated
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et al, 2006). Also, it has been reported that specific functional
aspects of innate immune cells are pivotal for intestinal
homeostasis, inflammation, and tumorigenesis. Exemplary, a
T-cell-specific knockout mouse model of Smad4, a downstream
component of TGFb and BMP signalling, resulted in intestinal
tumorigenesis (Kim et al, 2006). Recently, Kitamura et al (2007)
showed that immature myeloid cells (iMCs) are recruited from the
bone marrow to the tumour invasion front of compound
heterozygous cis-Apc
þ/D716;Smad4
þ/– mice with invasive intest-
inal adenomacarcinoma. These CD34
þ iMCs promote tumour
growth by expression of the matrix metalloproteinases, MMP9 and
MMP2, and the CC-chemokine receptor 1 (CCR1), and migrate
towards the CCR1 ligand CCL9, highly increased in the tumour
epithelium. Greten et al (2004) reported that activation of the
transcription factor NFkB (nuclear factor-kB), a key mediator of
inflammation, has a critical role in the development of tumours
resulting from chronic inflammation or exogenous mutagens,
induced by exposure to dextran sulphate sodium salt and
Azoxymethane (AOM). Moreover, genetic ablation of MyD88, a
signalling adaptor of Toll-like receptors in the innate immune
system, was shown to reduce mortality due to intestinal
tumorigenesis in Apc
þ/Min mice (Rakoff-Nahoum and Medzhitov,
2007). In fact, Auguste et al (2007) have shown that liver
metastases formation coincides with an inflammatory,
TNFa-mediated, host organ response. This inflammatory reaction
upregulates cell adhesion molecules in the liver stromal micro-
vasculature and supports tumour cell arrest and extravasation in a
metastatic mouse model induced by intrasplenic injection of the
highly metastatic human colorectal cancer cell line, CX-1. Finally,
adipocytes have also been reported to promote proliferation of
colon cancer cells (Amemori et al, 2007).
Overall, these data indicate that the host inflammatory response
is a key mediator of tumour survival, extravasation, and metastasis
formation. In fact, a broad spectrum of diverse cell types from
within the tumour microenvironment may contribute to the
modulation of b-catenin activation and cancer stemness, thus
promoting intestinal tumour progression and even initiation. In
this regard, tumour progression and cancer stemness may
significantly be determined by a context-dependent modulation
of b-catenin activity in colorectal cancer.
HYPOXIA- AND OXIDATIVE STRESS-INDUCED
SELECTION OF TUMOUR CELLS DISPLAYING
NUCLEAR b-CATENIN ACCUMULATION AND
CANCER STEMNESS
Besides the specific stromal cell types, other factors from within
the tumour microenvironment are likely to play significant roles in
promoting cancer stemness and malignant behaviour through
b-catenin nuclear accumulation and signalling. Hypoxia underlies
progressive tumour growth in the majority of solid tumours
(Sullivan and Graham, 2007). During tumour growth, certain areas
are exposed to reduced oxygen tension due to a disturbed
microcirculation and inadequate blood supply. Hypoxic condi-
tions are often found in the invasive front of colorectal carcinomas
in association with stabilisation of the HIF1a (hypoxia-inducible
factor-1a) transcription factor (Sivridis et al, 2005). HIF1a
stabilisation results in transcriptional regulation of a variety of
target genes, including the proangiogenic factors vascular endo-
thelial growth factor and PDGF (Koukourakis et al, 2006). In
fact, Cleven et al (2007), showed that expression of HIF1a in the
stromal compartment correlates with poor prognosis in colorectal
cancer. Moreover, loss of MUTYH function, a DNA glycogylase
involved in base excision repair caused by oxidative stress, results
in increased susceptibility to spontaneous and oxidative stress-
induced (by the oxidative reagent KbrO3) intestinal tumorigenesis
(Sakamoto et al, 2007). These data indicate that hypoxia and
oxidative stress play a pivotal role in colorectal cancer progression.
Notably, Kaidi et al (2007) reported that HIF1a binds directly to
b-catenin in the nucleus, thus linking hypoxia-induced cellular
changes to b-catenin activation.
BIOLOGICAL EFFECTS OF NUCLEAR b-CATENIN
ACCUMULATION
The nuclear accumulation of b-catenin observed in colorectal
cancer cells distributed along the invasive front may not only
reflect a specific level of canonical Wnt activity but also indicate
the activation of additional signalling pathways. It has been shown
that, in the nucleus, b-catenin binds to a broad spectrum of
transcription factors other than TCF and LEF and modulates a
plethora of downstream targets possibly contributing to cancer
stemness and malignancy (Table 1). As stated above, hypoxia
induces stabilisation of HIF1a and its interaction with b-catenin,
thereby competing with TCF/LEF1 transcription factors for
b-catenin binding in colorectal cancer cells (Kaidi et al, 2007).
Stabilisation and binding of HIF1a to b-catenin results in
inhibition of Wnt reporter activity, induction of cell-cycle arrest,
survival, and cellular adaptation, and is likely to contribute to the
malignant and invasive behaviour of tumour cells exposed to
reduced oxygen tension. Similarly, oxidative stress stimulates
b-catenin binding to the Forkhead box O transcription factors,
inducing cell-cycle arrest and survival (Essers et al, 2005).
Through interaction with Smads (including Smad1, Smad3, and
Smad4), b-catenin may also coregulate a subset of common TGFb,
BMP, and Wnt target genes (Nishita et al, 2000; Hussein et al, 2003;
Chakladar et al, 2005; Hu and Rosenblum, 2005). Transforming
growth factor-b and BMP signalling are known to be important
regulators of epithelial cell function. Synergism among TGFb,
BMP, and Wnt signalling pathways may represent a significant
determinant of malignant behaviour in tumour cells. b-Catenin
binding to Smad7, an inhibitory molecule induced upon TGFb
pathway activation as part of a negative feedback loop, has also
been reported to be rate limiting for TGFb-induced apoptosis
(Edlund et al, 2005) and induces proteolytic degradation of
b-catenin (Han et al, 2006). When c-Jun, a stress- and growth
factor-induced transcription factor, is recruited to the TCF/LEF1/
b-catenin complex, synergistic effects on intestinal tumorigenesis
are observed (Nateri et al, 2005). Also, gut-specific deletion of
c-Jun decreased tumour multiplicity and increased life span in the
Apc
Min mouse model for intestinal cancer. Recently, both c-Jun
and its known heterodimerisation partner, c-Fos, were reported to
bind directly to b-catenin (Toualbi et al, 2007). Therefore, binding
of b-catenin to different interaction partners in the nucleus may
direct both TCF/LEF1-dependent and -independent transcriptional
regulation.
Hence, in view of this observed promiscuity for nuclear
transcription factors (Table 1), b-catenin is likely to represent a
central node where different signals converge and are subsequently
coordinated to regulate tissue homeostasis under physiological
conditions and cancer stemness in the context of tumour–stroma
interactions. Because the putative b-catenin interaction partners
are themselves regulated by extracellular stimuli, it is plausible that
the subsequent effects on b-catenin activation and possibly cancer
stemness are modulated in a context-dependent manner. In fact, b-
catenin has been reported to interact directly with several growth
factor receptors, including EGFR (epidermal growth factor
receptor, ErbB1), Met (the receptor for HGF), TGFRII (the
receptor that is activated upon TGF stimulation), and KIT (the
receptor for stem cell factor; Hoschuetzky et al, 1994; Monga et al,
2002; Tian and Phillips, 2002; Kajiguchi et al, 2008). These
interactions result in b-catenin Tyr phosphorylation, stabilisation,
and increased transcriptional activity.
Tumour–stroma interactions in b-catenin-driven cancer stemness
NH Le et al
1889
British Journal of Cancer (2008) 98(12), 1886–1893 & 2008 Cancer Research UKTable 1 Nuclear b-catenin-binding partners
Protein Interaction and biological significance Reference
14-3-3-z Binds b-catenin and stabilises it, Akt dependent Tian et al (2004)
Akt Phosphorylates b-catenin at S552 and increases cytoplasmic pool, increases binding
to 14-3-3, increases transcriptional activity
Fang et al (2007)
AR (androgen receptor) Binds b-catenin, augments AR activity, inhibits TCF-dependent transcription Yang et al (2002)
AP1 and Smad3/4 Complex with b-catenin and TCF/Lef1 to activate gastrin target gene Chakladar et al (2005)
BCL9 (Legless) Binds b-catenin and TCF/LEF1, increases transcription, Pygopus dependent Kramps et al (2002)
B9L/BCL9-2 (BCL9-like protein) Binds b-catenin, increases transcription, induces EMT Adachi et al (2004); Brembeck
et al (2004)
Brg-1 (chromatin remodelling
factor)
Binds b-catenin, increases transcription Barker et al (2001)
c-Jun (phosphorylated) Binds b-catenin and TCF/LEF1 in a JNK- and b-catenin-dependent manner, knockout
decreases tumour multiplcity in Apc
min animals
Nateri et al (2005); Toualbi
et al (2007)
c-Fos Binds b-catenin, increases transcription Toualbi et al (2007)
CARM1 (coactivator-associated
arginine methyltransferase)
Binds b-catenin, increases transcription Koh et al (2002)
CBP (CREB-binding protein) Binds b-catenin Takemaru and Moon (2000)
cdx1 and cdx2 (homeodomain
transcription factors)
Decreases b-catenin Tyr phosphorylation, decreases transcription, induces E-cadherin
adhesion
Guo et al (2004); Ezaki et al
(2007)
Chibby (nuclear protein) Binds b-catenin, inhibits transcription Takemaru et al (2003)
CREB (cyclic AMP response
element binding protein)
Binds b-catenin, induces expression of WISP-1 (Wnt-1-induced secreted protein 1) Xu et al (2000)
cul4B (Cullin4B/E3-ubiquitin ligase) Binds b-catenin and induces its proteolytic degradation Tripathi et al (2007)
Duplin (axis duplication inhibitor) Binds b-catenin in nucleus and inhibits transcription Sakamoto et al (2000)
EBP50 (PDZ-containing protein) Binds b-catenin, increases transcription Shibata et al (2003)
emerin (type II inner nuclear
membrane protein)
Binds b-catenin resulting in its cytoplasmic retention and decreased transcriptional
activity
Markiewicz et al (2006)
ERa (estrogen receptor) Binds b-catenin, increases transcription Kouzmenko et al (2004)
ezh2 (enhancer of zeste homolog
2, polycomb group protein)
Binds b-catenin and ERa Shi et al (2007)
FHL2 (four and a half of LIM-only
protein 2,
LIM coactivator)
Binds b-catenin, increases transcription Wei et al (2003); Martin et al
(2002)
FOXO (insulin- and oxidative stress
signaling-induced transcription
factor)
Binds b-catenin resulting in increased FOXO target gene transcription Essers et al (2005)
FUS (fusion/translocated in
liposarcoma, TLS)
Binds and increases b-catenin, regulates pre-mRNA splicing Sato et al (2005)
GRIP1 (p160 coactivator of AR) Binds b-catenin, augments AR activity Li et al (2004)
Groucho/TLE (transcriptional
repressor)
Binds b-catenin and is subsequently displaced from TCF/LEF1 Daniels and Weis (2005)
HIF1a (hypoxia inducible factor) Binds b-catenin, competes with TCF/LEF1, induces survival and cellular adaptation to hypoxia Kaidi et al (2007)
hARD1 (human arrest defective 1,
acetyltransferase)
Binds and acetylates b-catenin, increases transcription Lim et al (2006)
I-mfa (inhibitor of MyoD Family a) Binds b-catenin, relieving I-mfa-mediated gene repression Pan et al (2005)
ICAT (inhibitor of b-catenin and
TCF-4)
Binds b-catenin, represses transcription Tago et al (2000)
IKKa (IkB kinase a) Binds b-catenin, inhibits its ubiquitination, increases transcription Lamberti et al (2001)
IKKb (IkB kinase b) Binds b-catenin, inhibits transcription Lamberti et al (2001)
LRH-1 (orphan nuclear receptor) Binds b-catenin, induces proliferation Botrugno et al (2004)
LZTS2 (leucine zipper tumor
suppressor 2)
Binds b-catenin, inhibits transcription Thyssen et al (2006)
Mediator (MED12 subunit) Binds b-catenin, increases transcription Kim et al (2006)
Mitf (microphthalmia-associated
transcription factor)
Binds b-catenin and competes with TCF/LEF1 to activate mitf target genes,
important for melanocyte development
Schepsky et al (2006)
NFkB, p50 subunit Binds b-catenin, decreases NFkB DNA binding, transactivation activity, regulates
TNFa-induced CRP (C-reactive protein, acute-phase response protein) expression
Deng et al (2002); Sun et al
(2005); Choi et al (2007)
Nurr1 (orphan nuclear receptor) Binds b-catenin, increases transcription Kitagawa et al (2007)
oct3/4 Binds b-catenin in ES cells, upregulates Nanog Takao et al (2007)
p68 (DEAD box family of RNA
helicases)
Binds b-catenin upon PDGF-induced Tyr phosphorylation of p68, increases
transcription and EMT
Yang et al (2006)
p300 Binds and acetylates b-catenin, increases transcription Sun et al (2000); Hecht et al
(2000)
Parafibromin (component of
polymerase-associated factor 1
(PAF1) complex)
Binds b-catenin, increases transcription, Pogypus dependent Mosimann et al (2006)
Pin1 (prolyl isomerase) Binds b-catenin, displaces it from APC, stabilises it and induces transcription, overexpressed in
human tumours
Ryo et al (2001)
Pitx2 (bicoid-related transcription
factor)
Induced by Wnt/Dvl/b-catenin, increases transcription Kioussi et al (2002)
Pontin52 (nuclear protein) Binds b-catenin Bauer et al (1998)
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Despite the clear genetic prerequisite for mutations in downstream
components of the Wnt/b-catenin-signalling pathway that result in
its constitutive activation, heterogeneous intratumour expression
and subcellular localisation of b-catenin is commonly observed in
colorectal cancer. Tumour cells located at the invasive front display
increased nuclear b-catenin accumulation, suggesting that this
nonrandom intracellular distribution earmarks and underlies
tumour heterogeneity and malignancy. Therefore, it has been
postulated that b-catenin may play a significant role in cancer
stemness, driving invasion and metastasis. b-Catenin regulation is
already known to be important during homeostasis, as Wnt/b-
catenin signalling governs several adult stem cell niches, including
the intestinal crypt. The tumour microenvironment may play a
central role in the malignant transformation of tumour cells by
locally modifying b-catenin activity at the primary tumour site as
well as preparing secondary organ sites for metastatic growth.
Individual ‘stromal signatures’, that is, characteristic of stromal cell
function, inflammation, and other stress-induced responses, may
determine disease progression, responsiveness to different (adju-
vant) therapeutic strategies, and, thus, prognosis and survival for
colorectal cancer patients. Stromal cells have even been suggested as
possible targets for tailor-made therapeutic interventions for
intestinal tumorigenesis, rather than parenchymal cells. Here, we
propose that the functional characterisation of additional b-catenin-
binding partners in these alleged CSCs will improve our under-
standing of malignancy and invasion and open future perspectives
for a metastasis-free survival to colorectal cancer patients.
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